Shineco don launch blockchain platform to tokenize cellular assets for Ethereum
Shineco Inc., one stem-cell biotech company, don join hand with Plus Me Limited to launch new blockchain platform for Ethereum. Dis platform dey use smart contracts and non-fungible digital identifiers (NFDIs) to confirm ownership and origin of correct cellular assets. Shineco go issue Cell Infusion Redemption Tokens wey fit be exchange for cell-therapy services for centers wey dem get partnership with. Dis new kind tokenization framework dey solve high cost, assets wey no easy to sell, and origin issues for biotech. Token holders go get governance rights, including future DAO voting to guide how ecosystem go develop. As Shineco buy cell-storage provider, dem don secure full on-chain and off-chain infrastructure, putting dem front for decentralized biotech economies.
Bullish
Di launch wey dem do for blockchain platform to tokenise cellular assets for Ethereum na beta oga development. E dey widen Ethereum real-world asset use dem use cases, fit make ETH demand and tokens dem wey follow increase. Shineco initiative fit attract new institutional and retail interest by solving provenance, liquidity and cost wahala for biotech. The place wey smart contracts and DAO governance join add layers of transparency and community-driven growth. For short term, the announcement fit make trading activities around biotech-token projects and ETH increase. For long term, bidi on-chain infrastructure for biological assets fit encourage more tokenization ventures and e go reinforce good feelings for the bigger DeFi and NFT markets.